EBAMed annonces EUR 2.4 million grant
Share this article
EBAMed receives a EUR 2.4 million grant from the EU Horizon 2020 Research and Innovation Program
EBAMed is glad to announce the award of a non-dilutive EUR 2.4 M grant by the Enhanced European Innovation Council (EIC) within the framework of the competitive EU Horizon 2020 Research and Innovation Program under grant agreement No 954783. The grant will allow the company to pursue the development of its cardiac motion management product for the non-invasive treatment of heart arrhythmias. The Geneva-based startup will be able to optimise the proton therapy medical device’s hardware and software components and perform a first-in-human study, planned to begin in 2021.